Back to Search Start Over

2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children.

Authors :
Kissling, Esther
Valenciano, Marta
Pozo, Francisco
Vilcu, Ana‐Maria
Reuss, Annicka
Rizzo, Caterina
Larrauri, Amparo
Horváth, Judit Krisztina
Brytting, Mia
Domegan, Lisa
Korczyńska, Monika
Meijer, Adam
Machado, Ausenda
Ivanciuc, Alina
Višekruna Vučina, Vesna
van der Werf, Sylvie
Schweiger, Brunhilde
Bella, Antonino
Gherasim, Alin
Ferenczi, Annamária
Source :
Influenza & Other Respiratory Viruses. Jul2018, Vol. 12 Issue 4, p423-437. 15p.
Publication Year :
2018

Abstract

Background: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods: We used the test‐negative design in a multicentre case‐control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza‐like illness (ILI) laboratory‐confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza‐positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5‐46.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5‐56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17502640
Volume :
12
Issue :
4
Database :
Academic Search Index
Journal :
Influenza & Other Respiratory Viruses
Publication Type :
Academic Journal
Accession number :
130228839
Full Text :
https://doi.org/10.1111/irv.12520